Pooneh Akhavan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pooneh Akhavan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- J. Carter Thorne
J.C. Thorne, MD, FRCPC, Assistant Past Professor, Department of Medicine, University of Toronto; Medical Director, The Arthritis Program; Board Chair Centre of Arthritis Excellence, Newmarket, Ontario, Canada
4 shared publications - Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
4 shared publications - Bindee Kuriya
Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada
3 shared publications - Mohammad Movahedi
Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 2C4, Canada
3 shared publications - Sibel Zehra Aydin
Division of Rheumatology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada
3 shared publications - Alexandra Legge
Division of Rheumatology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in Joint Bone Spine
Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
- 31 October 2026
- Published by Elsevier in Joint Bone Spine
Open AccessTitle: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)
- 25 September 2026
- Published by Wiley in Arthritis Care & Research
Defining Difficult‐to‐Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late Difficult‐to‐Treat Rheumatoid Arthritis Phenotypes
Objective: Despite advances in treat‐to‐target strategies, a subset of patients with rheumatoid arthritis (RA) remains refractory to multiple therapies and is classified as having difficult‐to‐treat RA (D2T‐RA). Although EULAR has proposed classification criteria for D2T‐RA, these patients remain variably identified in real‐world practice because of heterogeneous applications. We aimed to compare the preformance of published applications of the EULAR D2T‐RA criteria in a real‐world RA cohort and to determine weather the timing of D2T‐RA development could distinguish early from late D2T‐RA phenotypes. Methods: Using data from the Ontario Best Practices Research Initiative, a longitudinal real‐world RA registry, we evaluated four literature‐derived adaptations of the EULAR D2T‐RA definition among patients initiating their first advanced therapy. These definitions differed in disease activity requirements, follow‐up duration, and treatment count thresholds. We assessed prevalence, agreement between definitions, and explored different temporal anchors for classifying early versus late D2T‐RA. Results: Among 1,121 patients with RA (mean age 56.0 years; 80.7% female; mean disease duration of 8.4 years), 202 (18%) fulfilled at least one of four D2T‐RA definitions. Prevalence varied substantially across definitions, ranging from 5.5% (definition 4) to 11.7% (definition 2). Definitions 1 and 2, which incorporated multiple disease activity measures, identified the largest proportion of patients, whereas definition 4, which is defined solely by initiation of a third advanced therapy, was most restrictive. Overlap between definitions was modest, with only 44% of patients meeting all definitions 1 through 3, whereas definition 4 identified a distinct group with no overlap with the other definitions, suggesting that these classification approaches capture different patient subsets and are not interchangeable. In temporal analyses, anchoring the D2T‐RA onset to the initiation of the first advanced therapy, a two‐year threshold—selected for its clinical relevance and balanced group sizes—classified approximately 40% of patients as early and approximately 60% as late D2T‐RA. Conclusion: The applications of D2T‐RA criteria are not interchangeable and vary widely in patient capture. A two‐year threshold anchored to the first initiation of advanced therapy offered a clinically balanced early–late D2T‐RA framework. Harmonized, multidimensional definitions incorporating disease activity and temporal stratification are needed to improve phenotyping, prognostication, and cross‐study comparability.
- 25 September 2026
- Published by Wiley in Arthritis Care & Research
Defining Difficult‐to‐Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late Difficult‐to‐Treat Rheumatoid Arthritis Phenotypes
Objective: Despite advances in treat‐to‐target strategies, a subset of patients with rheumatoid arthritis (RA) remains refractory to multiple therapies and is classified as having difficult‐to‐treat RA (D2T‐RA). Although EULAR has proposed classification criteria for D2T‐RA, these patients remain variably identified in real‐world practice because of heterogeneous applications. We aimed to compare the preformance of published applications of the EULAR D2T‐RA criteria in a real‐world RA cohort and to determine weather the timing of D2T‐RA development could distinguish early from late D2T‐RA phenotypes. Methods: Using data from the Ontario Best Practices Research Initiative, a longitudinal real‐world RA registry, we evaluated four literature‐derived adaptations of the EULAR D2T‐RA definition among patients initiating their first advanced therapy. These definitions differed in disease activity requirements, follow‐up duration, and treatment count thresholds. We assessed prevalence, agreement between definitions, and explored different temporal anchors for classifying early versus late D2T‐RA. Results: Among 1,121 patients with RA (mean age 56.0 years; 80.7% female; mean disease duration of 8.4 years), 202 (18%) fulfilled at least one of four D2T‐RA definitions. Prevalence varied substantially across definitions, ranging from 5.5% (definition 4) to 11.7% (definition 2). Definitions 1 and 2, which incorporated multiple disease activity measures, identified the largest proportion of patients, whereas definition 4, which is defined solely by initiation of a third advanced therapy, was most restrictive. Overlap between definitions was modest, with only 44% of patients meeting all definitions 1 through 3, whereas definition 4 identified a distinct group with no overlap with the other definitions, suggesting that these classification approaches capture different patient subsets and are not interchangeable. In temporal analyses, anchoring the D2T‐RA onset to the initiation of the first advanced therapy, a two‐year threshold—selected for its clinical relevance and balanced group sizes—classified approximately 40% of patients as early and approximately 60% as late D2T‐RA. Conclusion: The applications of D2T‐RA criteria are not interchangeable and vary widely in patient capture. A two‐year threshold anchored to the first initiation of advanced therapy offered a clinically balanced early–late D2T‐RA framework. Harmonized, multidimensional definitions incorporating disease activity and temporal stratification are needed to improve phenotyping, prognostication, and cross‐study comparability.
- Open Access
- 17 July 2026
- Published by MDPI AG in Inflammation Journal
- Vol. 1 (1) , 2
Impact of Rheumatoid Arthritis Treatment Classes on Cardiovascular, Thromboembolic, Cancer Outcomes, and All-Cause Mortality: A Population-Based Cohort Study
Background: Rheumatoid arthritis (RA) is linked to increased risks of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality. However, differences in these risks by treatment class—particularly among older adults with cardiovascular (CVD) risk factors—remain unclear. Methods: We conducted a population-based cohort study using Ontario administrative data. Patients aged ≥67 years with incident RA (2008–2013) were followed through 2023. Outcomes included healthcare utilization for MACE and VTE, all-cause mortality, and cancer-related encounters. Time-varying treatment groups were: no csDMARD/advanced therapy (AT), glucocorticoids (GC) only, csDMARDs (reference), and biologic/targeted synthetic DMARDs (b/tsDMARDs). Weighted Fine–Gray models within a marginal structural framework were used, stratified by baseline CVD risk. Results: Among 10,058 patients, 80% had high CVD risk. Compared with csDMARDs, untreated patients (SHR 15.0; 95% CI 13.8–16.2) and GC users (SHR 1.29; 95% CI 1.13–1.47) had higher MACE risk, while AT use was associated with lower risk (SHR 0.53; 95% CI 0.37–0.77). Similar patterns were observed in low-risk patients. AT use was not associated with VTE. Untreated and GC users had increased mortality, whereas AT use reduced mortality. Increased cancer-related utilization was observed only in untreated patients. Conclusion: Treatment type strongly influences major outcomes in older adults with RA, underscoring the importance of integrating CVD and thrombotic risk into therapeutic decisions.
- 17 July 2026
- Published by MDPI AG in Inflammation Journal
- Vol. 1 (1) , 2
Open AccessImpact of Rheumatoid Arthritis Treatment Classes on Cardiovascular, Thromboembolic, Cancer Outcomes, and All-Cause Mortality: A Population-Based Cohort Study
Background: Rheumatoid arthritis (RA) is linked to increased risks of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality. However, differences in these risks by treatment class—particularly among older adults with cardiovascular (CVD) risk factors—remain unclear. Methods: We conducted a population-based cohort study using Ontario administrative data. Patients aged ≥67 years with incident RA (2008–2013) were followed through 2023. Outcomes included healthcare utilization for MACE and VTE, all-cause mortality, and cancer-related encounters. Time-varying treatment groups were: no csDMARD/advanced therapy (AT), glucocorticoids (GC) only, csDMARDs (reference), and biologic/targeted synthetic DMARDs (b/tsDMARDs). Weighted Fine–Gray models within a marginal structural framework were used, stratified by baseline CVD risk. Results: Among 10,058 patients, 80% had high CVD risk. Compared with csDMARDs, untreated patients (SHR 15.0; 95% CI 13.8–16.2) and GC users (SHR 1.29; 95% CI 1.13–1.47) had higher MACE risk, while AT use was associated with lower risk (SHR 0.53; 95% CI 0.37–0.77). Similar patterns were observed in low-risk patients. AT use was not associated with VTE. Untreated and GC users had increased mortality, whereas AT use reduced mortality. Increased cancer-related utilization was observed only in untreated patients. Conclusion: Treatment type strongly influences major outcomes in older adults with RA, underscoring the importance of integrating CVD and thrombotic risk into therapeutic decisions.
- Open Access
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.
- 15 July 2024
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 51 (9) , 940-941
Open AccessCanadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2
We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.